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genomic alterations that are critical to their disease development and
progression. For example, greater than 90% of the chronic myelogenous
leukemias (CML) are caused by the t(9;22)(q34;q11) or BCR/ABL trans-
location, whereas more than 75% of mantle cell lymphomas have the
t(11,14)(q13, 32) translocation (Kurzrock et al., 2003; Li et al., 1999).
Because these genomic alterations are frequently drivers of the onco-
genesis process, targeted therapies that inhibit the resultant aberrant
signaling pathways have achieved remarkable clinical success. Imatinib,
which inhibits the ABL tyrosine kinase, is considered one of the ﬁrst
molecularly targeted therapies for cancer (Druker et al., 2001). A recent
study suggested that patients with CML that are long-term responders to
imatinib have similar survival as the general population (Gambacorti-
Passerini et al., 2011). Today, many targeted therapies are in clinical use
or are under clinical development for the treatment of lymphomas and
leukemias (Johnston et al., 2010; Byrd et al., 2014).
Despite the success of targeted therapies, many genomic alter-
ations are considered “undruggable”. One such example is the above-
mentioned t(11,14)(q13, 32) translocation,which increases the expres-
sion of cyclin D1 (Musgrove et al., 2011). Another example of such an
undruggable target is CD22ΔE12, described in a research paper by
Uckun et al. in this issue of EBioMedicine (Uckun et al., 2014). Physiolog-
ically, CD22 negatively regulates cellular proliferation, and the
CD22ΔE12 deletion results in the release of this brake. The authors
demonstrated that CD22ΔE12 is associated with both pediatric and
adult B-precursor acute lymphoblastic leukemias (BPL). More impor-
tantly, they showed that knockdown of CD22ΔE12 with small interfer-
ing RNA (siRNA) decreased the tumor cells' clonogenicity, suggesting
that themutation is responsible for disease progression in BPL. Howev-
er, because the CD22ΔE12 mutation results in the lack of negative sig-
naling on cellular pathways, it is an undruggable target. Despite this,
the mutation is amenable to treatment by siRNA, as demonstrated by
the authors.
The idea of utilizing RNA interference for the treatment of diseases is
not new. As mentioned above, such a strategy can treat targets that are
considered undruggable and with far-reaching potential. The key chal-
lenge in siRNA clinical translation has been drug delivery. First, siRNAs
need to be preferentially delivered to diseased cells to avoid side effects
to normal cells. Second, siRNA needs to enter the target cells' cytosolDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.10.013.
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to weeks) and not permanent; such temporary effects may not last
long enough to alter the disease course. In recent years, many siRNA de-
livery strategies have been developed,mostly involving the use of nano-
particles. Nanoparticles can protect the siRNA fromdegradation and can
facilitate endosomal escape once the siRNA has been endocytosed by
the target cells (Kanasty et al., 2013). However, no siRNA-based thera-
pies have been approved for clinical use.
In the paper by Uckun et al., the investigators engineered a unique
polypeptide-based nanoparticle to deliver siRNA against CD22ΔE12
(Uckun et al., 2014). The nanoparticle contains a cell-penetratingmoie-
ty that can facilitate endosomal escape of the siRNA-nanoparticle com-
plex, solving one of the key challenges in siRNA delivery. The authors
demonstrated that their CD22ΔE12 siRNA-nanoparticle can indeed
knock down CD22ΔE12 and inhibit tumor cell growth. Their ﬁnding is
provocative in several aspects. First, they demonstrated that siRNA can
be an effective targeted therapy against genomic alterations. If there is
an effective delivery vehicle, novel siRNA-based treatments can be rap-
idly developed to address newly discovered oncogenic mutations. Sec-
ond, lymphomas and leukemias are intriguing diseases for siRNA
therapy. Unlike solid tumors where nanoparticle penetration is a con-
cern, liquid tumors are freely exposed to nanoparticle agents. Many liq-
uid tumors also have characteristic surface biomarkers, such as CD20,
that can be used for targeted drug delivery. Lastly, liquid tumor cells
have rapid turnover, which makes them potentially more susceptible
to the temporary effects of siRNA. Thus, this study suggests that nano-
particle siRNA formulations can be the next generation of targeted ther-
apy in liquid tumors. However, there are several critical challenges the
investigators need to overcome for the clinical translation of their tech-
nology. The authors did not evaluate the CD22ΔE12 siRNA-nanoparticle
in vivo. In vivo toxicity and biodistribution are critical to a nanoparticle
platform's ability as a delivery vehicle. The investigators will also need
to characterize the nanoparticle's stability in vivo. Peptide-based agents
are also at risk for immunogenicity, especially when the polypeptides are
not native to the human body. Moreover, while the cell-penetratingmoi-
ety is beneﬁcial for endosomal escape, it can also introduce additional sys-
temic toxicity. The authors also did not demonstrate that these CD22ΔE12
siRNA-nanoparticles can preferentially target leukemic cells over normal
cells.While normal cellsmay not harbor this deletion, lack of targeted de-
livery of the siRNA can minimize its therapeutic efﬁcacy and increase its
toxicity. Despite these limitations, this study identiﬁed CD22ΔE12 as a
key genomic alteration in BPL and found that a nanoparticle formulationthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
102 A.Z. Wang / EBioMedicine 1 (2014) 101–102of siRNA against CD22ΔE12 can achieve therapeutic effects in this disease.
Thisworkhighlights the potential of siRNAas targeted agents for lympho-
mas and leukemias.
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